Theory Paper IIDrNB Cardiology – Theory Notes

MANAGEMENT OF MECHANICAL PROSTHETIC HEART VALVE (PHV) THROMBOSIS

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

ICORE CONCEPTS AND CLINICAL URGENCY

  • The Clinical Emergency: Mechanical PHV thrombosis is a life-threatening complication, more common in the Mitral and Tricuspid positions due to lower flow velocities.
  • The Pathophysiology: It results from inadequate anticoagulation, leading to the formation of an obstructive clot that restricts leaflet motion, causing acute heart failure or systemic embolism.
  • The Critical Distinction: One must differentiate Thrombus (acute, soft, associated with sub-therapeutic INR) from Pannus (chronic, fibrous ingrowth, slow progression, independent of INR).

IIDIAGNOSTIC WORKUP FOR MANAGEMENT

  • Cine-Fluoroscopy: The gold standard for assessing leaflet mobility. A restricted “opening or closing angle” confirms obstruction.
  • Transthoracic (TTE) and Transesophageal Echo (TEE):
    • Essential to measure the Mean Gradient. An increase in gradient (e.g., doubling from baseline) is highly suggestive.
    • TEE is mandatory to quantify the size of the thrombus (measured in square cm or mm).
  • Multidetector CT (MDCT): Highly accurate in differentiating low-attenuation thrombus from high-attenuation pannus.

IIIMANAGEMENT RECOMMENDATIONS (2021 ESC/EACTS & 2020 ACC/AHA)

The choice of therapy depends on the Clinical Stability of the patient and the Size/Location of the thrombus.

AObstructive Thrombus (Critical Stenosis)

  • Emergency Surgery (ESC Class I): Preferred for critically ill patients (NYHA Class 3 or 4) without serious comorbidity who are good surgical candidates. (2020 ACC/AHA gives a Class I recommendation to either urgent low-dose slow-infusion fibrinolysis or emergency surgery for symptomatic obstructive left-sided thrombosis.)
  • Fibrinolysis (ESC Class IIa): Considered if:
    • Surgery is high-risk or unavailable.
    • The thrombus is on the Right Side (Tricuspid).
    • The patient is in extremis (too unstable for the OR).

BNon-Obstructive Thrombus (Incidental Finding)

  • Small Thrombus (Less than 10 mm or 0.8 square cm): Managed with optimized Heparin/Warfarin therapy.
  • Large Thrombus (Greater than 10 mm):
    • If associated with embolism: Surgery or Fibrinolysis is indicated.
    • If asymptomatic: Intense anticoagulation is tried first; if the thrombus does not regress, surgery is indicated to prevent future embolism.

IVTHE EVIDENCE BASE: LANDMARK TRIALS

  • The TROIA Study (Özkan et al., 2013): A large multicentre observational registry of TEE-guided fibrinolysis. Low-Dose, Slow-Infusion Tissue Plasminogen Activator (tPA) (25 mg over 6 hours, repeated if needed) was associated with fewer complications (embolism and bleeding) than higher-dose rapid regimens while maintaining high success rates; the ultra-slow 25-hour infusion was evaluated in later studies by the same group.
  • PROACT and PROACT Xa Trials: PROACT showed that a lower INR target (1.5 to 2.0) after 3 months was non-inferior for thromboembolism with less bleeding in the On-X aortic valve specifically; PROACT Xa (apixaban versus warfarin in On-X aortic valves) was stopped early for excess thromboembolic events with apixaban, confirming that vitamin K antagonists remain mandatory for mechanical valves.
  • The “Slow Infusion” Evidence: Observational series suggest that slower infusion regimens are associated with lower embolic and bleeding complications in stable patients.

VFIBRINOLYSIS PROTOCOL (THE DISTINCTION DATA)

  • Agent: Recombinant tPA (Alteplase).
  • Dosage: 25 mg slow infusion over 6 to 25 hours.
  • Monitoring: Continuous TTE and Fluoroscopy to watch for leaflet “opening.”
  • Contraindications: Large Left Atrial Thrombus, recent stroke, or active internal bleeding.

VIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • The “Sub-Therapeutic” Reality: Many Indian cases are related to inconsistent drug supply or poor INR monitoring in rural areas.
  • The Fibrinolysis Preference: Given the limited access to cardiac surgical units in many parts of India, Low-Dose, Slow-Infusion Fibrinolysis is often the practical first-line strategy for stable patients in non-surgical centers.
  • The Streptokinase Alternative: While tPA is preferred, Streptokinase (2.5 Lakh units bolus followed by 1 Lakh units per hour) is still a valid, cost-effective alternative in Indian settings if tPA is unaffordable.
  • Post-Recovery Plan: Structured anticoagulation education before discharge is essential, together with Home INR monitoring if feasible to prevent recurrence.

Key references

  • Vahanian A, Beyersdorf F, Praz F, et al.: 2021 ESC/EACTS Guidelines for the management of valvular heart disease, European Heart Journal, 2022.
  • Otto CM, Nishimura RA, Bonow RO, et al.: 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, Circulation, 2021.
  • Özkan M, Gündüz S, Biteker M, et al.: Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial, JACC: Cardiovascular Imaging, 2013.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.